We then combined serum SV2A with NfL, GFAP, or p-tau217 by the serial test and found that the specificity of identifying AD from VaD improved from 83.72 to 97.7%, 93.0%, or 93.0%, respectively (Table 3). This evidence concerns the gene NEFL and Alzheimer disease.